Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 ...

Funding This study was supported by Terumo Neuro. Competing interests None declared. Provenance and peer review Not commissioned; externally peer reviewed. Supplemental material This content has been ...

/PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the commercial ...

Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships.

Terumo Neuro's SOFIA ™ Catheter Line is Backed By 10 Years of Proven Clinical Performance1-9 and Innovation – The New SOFIA™ Flow 88 Offers Reliable Trackability, Proximal Stability and ...

Terumo Interventional Systems (TIS), a division of Terumo Corporation, is pleased to announce the early commercial availability of its FDA-approved ROADSAVER™ Carotid Stent System. Indicated for use ...

Terumo Neuro (formerly MicroVention) announced that it launched its Sofia 88 neurovascular support catheter in the U.S.